Chapter review

Fitzgerald PMHNP board review. ch11. Substance-related Disorders. This is drive 6 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. Withdrawal Assessment Scales. Topic. COWS (Clinical Opiate Withdrawal Scale). Bottom Line Summary. - **Opioid withdrawal** presents as a multi-system physical syndrome involving autonomic hyperactivity (**tachycardia**, **piloerection**, **rhinorrhea**, **lacrimation**, **mydriasis**, **yawning**), gastrointestinal distress (**nausea**, **vomiting**, **diarrhea**, **abdominal cramps**), musculoskeletal pain (**arthralgias**, **muscle cramps**), and central nervous system arousal (**restlessness**, **tremor**, **anxiety**, **insomnia**). - The **Clinical Opiate Withdrawal Scale** (**COWS**) measures objective and subjective symptoms across 11 clinical items, dividing severity into four distinct numerical ranges: 5 to 12 for mild withdrawal, 13 to 24 for moderate withdrawal, 25 to 36 for moderately severe withdrawal, and scores above 36 for severe withdrawal. - Induction of **buprenorphine** requires establishing objective, active withdrawal on the **COWS** scale (typically moderate withdrawal with a score of 8 to 12 or higher) before administering the first dose. - **First-line** non-opioid pharmacotherapy for autonomic withdrawal symptoms is **clonidine**, an alpha-2 adrenergic agonist, combined with targeted non-opioid medications including **ondansetron** for nausea, **loperamide** for diarrhea, **NSAIDs** for body aches, and **trazodone** for insomnia. - **Naltrexone** is an opioid antagonist used for craving reduction in alcohol and opioid dependence, but it is strictly contraindicated in patients actively taking opioids or scheduled for elective procedures requiring opioid analgesia. - Distinguishing **opioid withdrawal** from **dextroamphetamine** or cocaine toxicity requires evaluating fluid signs: **piloerection**, **rhinorrhea**, **lacrimation**, and **diarrhea** confirm opioid withdrawal, whereas severe hypertension and psychomotor agitation without gastrointestinal hypermotility indicate stimulant toxicity. Clinical Teaching and Spoken Framework. Assessment and COWS Scoring Rules. The **Clinical Opiate Withdrawal Scale** (**COWS**) evaluates eleven distinct physical and behavioral parameters: resting heart rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability, and gooseflesh skin. A score of 5 to 12 represents mild withdrawal. A score of 13 to 24 represents moderate withdrawal. A score of 25 to 36 represents moderately severe withdrawal. Any score above 36 indicates severe withdrawal. For definitive Medication-Assisted Treatment of **opioid use disorder**, **buprenorphine** (a partial mu-opioid agonist) or **methadone** (a full mu-opioid agonist) represents the **first-line** standard of care. For non-opioid symptomatic management of autonomic hyperactivity, **clonidine** is the **first-line** agent. **Safety alert**: Administering **buprenorphine** or **naltrexone** prematurely while full mu-opioid agonists are still bound to central receptors triggers precipitated withdrawal. This causes an immediate, severe displacement of full agonists, resulting in intense physical distress. **Board trap**: Questions frequently present a patient with pupillary dilation and tachycardia to test your ability to differentiate opioid withdrawal from sympathomimetic intoxication. Look for autonomic fluid losses such as **lacrimation**, **rhinorrhea**, and **diarrhea** to confirm opioid withdrawal. Severe hypertension accompanied by psychomotor agitation without gastrointestinal distress points to stimulant toxicity such as **dextroamphetamine**. **Board trap**: Test writers often describe a patient requesting **naltrexone** for alcohol craving who has an upcoming surgical or dental procedure. Prescribing **naltrexone** in this situation is a classic distractor trap because blocking mu-opioid receptors prevents effective perioperative pain control with standard opioid analgesics. Sample Exam Questions. Question 1. Match the substance with the corresponding withdrawal symptoms: A. Depressed mood, fatigue, vivid dreams, and psychomotor agitation. B. Muscle cramps, arthralgia, and diarrhea. C. Increased heart rate, increased blood pressure, diaphoresis, hand tremor, agitation, and hallucinations. D. Severe cognitive impairment, ataxia, and nystagmus without autonomic signs. Pause. Answer. Keyed letter: B. Why correct: Option B describes multi-system **opioid withdrawal**, which prominently features musculoskeletal joint and muscle aches (**arthralgias** and cramps) along with gastrointestinal hypermotility (**diarrhea**). Why the other choices are wrong: - A: Depressed mood, fatigue, vivid dreams, and psychomotor agitation characterize stimulant withdrawal, such as from **amphetamines** or **cocaine**. - C: Increased heart rate, elevated blood pressure, diaphoresis, hand tremor, agitation, and hallucinations characterize acute **alcohol** or sedative-hypnotic withdrawal. - D: Severe cognitive impairment, ataxia, and nystagmus without autonomic signs indicate acute central nervous system neurotoxicity or sedative intoxication rather than opioid withdrawal. Question 2. Dana, a 44-year-old registered nurse, is preparing for discharge from a 30-day inpatient treatment facility for alcohol and methamphetamine dependence. She wishes to start a medication to help keep her abstinent from alcohol. She has extensive dental work planned to begin within the next month. Which medication would be contraindicated given this information? A. Disulfiram B. Naltrexone C. Acamprosate D. Sertraline Pause. Answer. Keyed letter: B. Why correct: **Naltrexone** is a mu-opioid receptor antagonist. Because Dana has upcoming extensive dental work that will require opioid analgesics for pain management, **naltrexone** is contraindicated because it blocks opioid receptors and prevents effective perioperative pain relief. Why the other choices are wrong: - A: Disulfiram inhibits aldehyde dehydrogenase to produce a physical aversion reaction when alcohol is consumed, but it does not block opioid pain medications. - C: Acamprosate modulates GABA and glutamate pathways, is excreted renally, and does not interfere with opioid pain management during dental procedures. - D: Sertraline is an SSRI antidepressant that does not interact with mu-opioid receptors, although it is not a primary anticraving agent for alcohol. Question 3. A 19-year-old man is brought to the emergency department by his friends who are concerned about his health. Physical examination reveals muscle weakness, dilated pupils, heart rate of 140 beats per minute, and blood pressure of 180 over 115 mmHg. His friends report he may have taken something orally about two hours ago. Which of the following is the most likely illicit substance? A. Cannabis B. Dextroamphetamine C. Diazepam D. Oxycodone Pause. Answer. Keyed letter: B. Why correct: **Dextroamphetamine** is a potent sympathomimetic stimulant that produces severe tachycardia (140 beats per minute), marked hypertension (180 over 115 mmHg), pupillary dilation, and muscle weakness or psychomotor agitation. Why the other choices are wrong: - A: Cannabis typically causes mild conjunctival injection, increased appetite, and mild tachycardia, but not severe malignant hypertension of 180 over 115 mmHg. - C: Diazepam is a benzodiazepine central nervous system depressant that causes sedation, slurred speech, and hypotension rather than a severe sympathetic surge. - D: Oxycodone is a full mu-opioid agonist that causes pupillary constriction, respiratory depression, bradycardia, and hypotension, which is the direct opposite of this patient's clinical presentation. 💡 Want to test your recall on the exact **COWS** scoring cutoffs or compare **CIWA** versus **COWS** monitoring protocols next? Next. New section. Opioid Use Disorder (OUD) MAT. Topic. Buprenorphine Properties. Bottom Line. * **buprenorphine** is a **partial mu-opioid receptor agonist** and **kappa-opioid receptor antagonist** indicated for **opioid use disorder** medication-assisted treatment (**MAT**). * **ceiling effect**: **buprenorphine** demonstrates a ceiling effect on respiratory depression and euphoria, making it safer in overdose compared to full mu-agonists like **methadone** or **morphine**. * **high binding affinity**: **buprenorphine** has higher affinity for mu-opioid receptors than full agonists; giving it while full agonists are active displaces them and causes **precipitated withdrawal**. * **COWS initiation threshold**: **buprenorphine** initiation requires active, mild-to-moderate withdrawal with a **Clinical Opioid Withdrawal Scale** (**COWS**) score of **11 to 12** or higher. * **initiation timeline**: wait at least **12 to 24 hours** after short-acting opioids and **48 to 72 hours** after long-acting opioids like **methadone** before administering **buprenorphine**. * **combination formulation**: **buprenorphine/naloxone** (**Suboxone**) uses a **4:1 ratio**; **naloxone** has minimal sublingual bioavailability but precipitates severe withdrawal if crushed and injected, preventing parenteral misuse. * **monotherapy exception**: **buprenorphine** monotherapy without **naloxone** (**Subutex**) is reserved for **pregnancy** or severe **naloxone** allergy. * **symptom management**: non-opioid adjuncts during withdrawal include **clonidine** for autonomic hyperactivity, **ondansetron** for nausea, **loperamide** for diarrhea, NSAIDs for body aches, and **trazodone** for insomnia. Buprenorphine Properties and Clinical Management. Pharmacology and Mechanism. * **partial agonist**: **buprenorphine** binds mu-opioid receptors as a partial agonist and kappa receptors as an antagonist. * **ceiling effect**: maximal respiratory depression and euphoria plateau at therapeutic doses, lowering lethal overdose risk relative to full mu-agonists like **methadone**. * **receptor affinity**: mu-receptor affinity is extremely strong, tightly occupying receptors and displacing full agonists. Initiation Protocols and COWS Score. * **precipitated withdrawal**: administering **buprenorphine** while full agonists occupy mu-receptors rapidly strips full agonists, producing acute, severe withdrawal. * **COWS scoring**: assess withdrawal severity using the **Clinical Opioid Withdrawal Scale** (**COWS**), which evaluates resting heart rate, sweating, restlessness, pupil size, bone or joint aches, runny nose, tearing, gastrointestinal upset, tremor, yawning, and irritability. * **COWS score ranges**: scores of **5 to 12** indicate mild withdrawal, **13 to 24** moderate withdrawal, **25 to 36** moderately severe withdrawal, and greater than **36** severe withdrawal. * **timing gate**: confirm a **COWS** score of at least **11 to 12** before the first dose. * **washout interval**: allow **12 to 24 hours** after short-acting opioids like heroin or oxycodone, and **48 to 72 hours** after long-acting opioids like **methadone**. Formulations and Misuse Deterrence. * **combination sublingual**: **buprenorphine/naloxone** (**Suboxone**) combines a **4:1 ratio**. * **sublingual absorption**: **naloxone** has negligible sublingual absorption, allowing **buprenorphine** therapeutic action. * **abuse deterrence**: intravenous or intranasal administration activates **naloxone**, blocking mu-receptors and triggering immediate withdrawal. * **monotherapy**: **buprenorphine** alone (**Subutex**) is preferred during **pregnancy** to protect the fetus from **naloxone** exposure. * **depot formulation**: **subcutaneously injected buprenorphine** (**Sublocade**) provides monthly maintenance after sublingual stabilization. First-Line Status and Safety Alerts. * **First-line**: **buprenorphine/naloxone** is a first-line office-based **MAT** choice for moderate to severe **opioid use disorder**. * **Safety alert**: verify active withdrawal using **COWS** prior to initiation to avoid severe **precipitated withdrawal**. * **Safety alert**: concurrent use of **buprenorphine** with **benzodiazepines** or central nervous system depressants increases toxicity and fatal respiratory depression risks. * **Board trap**: prescribing **naltrexone** or **Vivitrol** to a patient who requires opioid pain management for upcoming dental or surgical procedures within **30 days** blocks analgesia and causes acute withdrawal. Compare and Distinguish. Opioid Use Disorder MAT Agents. * **buprenorphine**: partial mu-agonist with ceiling effect, high affinity, office-based prescription, requires active withdrawal (**COWS** score **11 to 12** or higher) before starting. * **methadone**: full mu-agonist without ceiling effect, high overdose and QT prolongation risk, restricted to federally licensed Opioid Treatment Programs. * **naltrexone**: full mu-antagonist blocking opioid receptors and cravings, available orally or as monthly intramuscular **Vivitrol**, requires complete detoxification for **7 to 14 days** before starting. Opioid Withdrawal Adjuncts. * **clonidine**: alpha-2 adrenergic agonist for autonomic hyperactivity, tremors, and sweating. * **ondansetron**: serotonin 5-HT3 receptor antagonist for nausea and vomiting. * **loperamide**: peripheral mu-agonist for diarrhea. * **trazodone**: sedating antidepressant for insomnia. Sample Practice Questions. Sample Question 1. Question: Match the substance with the characteristic withdrawal symptoms below. Option A: depressed mood, fatigue, vivid dreams, and psychomotor agitation. Option B: muscle cramps, arthralgia, and diarrhea. Option C: increased heart rate, increased blood pressure, diaphoresis, hand tremor, agitation, and hallucinations. Which symptom cluster represents opioid withdrawal? * A. Option A * B. Option B * C. Option C * D. None of the above Pause. Answer: B. Why it is correct: Opioid withdrawal produces multi-system symptoms including gastrointestinal upset like diarrhea, muscle cramps, and joint aches (arthralgia), along with autonomic signs like rhinorrhea, lacrimation, and piloerection. Why the other choices are wrong: * A. Option A describes stimulant withdrawal, such as amphetamine or cocaine withdrawal, characterized by crash symptoms like fatigue, vivid dreams, and depressed mood. * B. Correct choice. * C. Option C describes alcohol or sedative-hypnotic withdrawal, characterized by autonomic hyperarousal, hand tremor, sweating, and potential hallucinations. * D. Option B accurately identifies the multi-system physical symptoms of opioid withdrawal. Test-taking pearl: Opioid withdrawal is intensely uncomfortable with muscle aches, bone pain, and diarrhea, but unlike severe alcohol withdrawal, it is rarely life-threatening in adults unless complicated by severe dehydration. Sample Question 2. Question: Dana, a 44-year-old registered nurse, is preparing to be discharged from a 30-day inpatient treatment facility for alcohol and methamphetamine dependence. She wishes to start a medication to help keep her abstinent from alcohol. She has extensive dental work planned to begin within the next month. Which medication would be contraindicated for use given this information? * A. Disulfiram * B. Naltrexone * C. Acamprosate * D. Sertraline Pause. Answer: B. Why it is correct: **Naltrexone** is a mu-opioid receptor antagonist. Because Dana has extensive dental work planned that will likely require opioid analgesics, **naltrexone** is contraindicated because it would block opioid pain relief or precipitate acute withdrawal if opioids are administered. Why the other choices are wrong: * A. **Disulfiram** causes a noxious physical reaction when alcohol is ingested but does not block opioid receptors or interfere with dental opioid analgesics. * B. Correct choice. * C. **Acamprosate** restores GABA and glutamate balance, is excreted by the kidneys, and does not interact with opioid analgesics. * D. **Sertraline** is an SSRI indicated for depression and anxiety, not a treatment for alcohol abstinence or contraindicated with opioids. Test-taking pearl: Always check upcoming medical or dental procedures before starting mu-opioid antagonists like **naltrexone**, as opioid blockage prevents effective acute pain management. Sample Question 3. Question: A 19-year-old man is brought to the emergency department by his friends who are concerned about his health. Physical examination reveals muscle weakness, dilated pupils, heart rate of 140 beats per minute, and blood pressure of 180 over 115 mmHg. His friends report he may have taken something orally about two hours ago. Which of the following is the most likely illicit substance ingested? * A. Cannabis * B. Dextroamphetamine * C. Diazepam * D. Oxycodone Pause. Answer: B. Why it is correct: Severe tachycardia, severe hypertension, dilated pupils (mydriasis), and muscle weakness represent acute sympathomimetic stimulant toxicity caused by **dextroamphetamine**. Why the other choices are wrong: * A. Cannabis toxicity typically causes conjunctival injection, dry mouth, increased appetite, and mild tachycardia, not severe malignant hypertension or severe mydriasis. * B. Correct choice. * C. Diazepam is a benzodiazepine CNS depressant causing sedation, slurred speech, ataxia, and respiratory depression rather than sympathomimetic surge. * D. Oxycodone is a full mu-opioid agonist causing pupillary constriction (miosis), respiratory depression, bradycardia, and hypotension, the exact opposite of this presentation. Test-taking pearl: Differentiate stimulant toxicity from opioid toxicity on boards by looking at pupils and vitals: stimulants dilate pupils and elevate vitals, whereas opioids constrict pupils and depress vitals. Next. Topic. Methadone Considerations. Bottom Line Summary. * **Methadone** is a **full mu-opioid receptor agonist** indicated for **Opioid Use Disorder (OUD)** maintenance and detoxification, requiring daily administration through federally certified Opioid Treatment Programs (OTPs) under SAMHSA oversight. * **Safety Alert**: **Methadone** causes dose-dependent **QTc prolongation** and torsades de pointes. Baseline ECG and follow-up monitoring are required, especially at doses exceeding 100 mg daily or when combined with QTc-prolonging psychotropics or antimicrobials. * **Pharmacokinetics**: Long elimination half-life of 24 to 36 hours (up to 55 hours) contrasts with a short analgesic duration of 4 to 8 hours. Tissue accumulation over 3 to 5 days means dose titration must occur slowly to prevent delayed fatal respiratory depression. * **First-Line**: **Methadone** and buprenorphine are **first-line** standard of care pharmacotherapies for pregnant patients with **Opioid Use Disorder (OUD)**, as abrupt opioid withdrawal triggers fetal distress, uterine contraction, and premature labor. * **Board Trap**: Prescribers cannot write an outpatient prescription for **methadone** to treat **Opioid Use Disorder (OUD)** in a standard clinic setting. Outpatient prescriptions for **methadone** are legally restricted to pain management only. * **Drug Interactions**: CYP3A4 and CYP2B6 inducers (e.g., carbamazepine, phenytoin, rifampin) rapidly decrease **methadone** plasma levels and precipitate acute opioid withdrawal, whereas CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole) increase **methadone** levels and toxicity risks. * **Opioid Withdrawal Identification**: Evaluated using the Clinical Opioid Withdrawal Scale (**COWS**), where a score of 5 to 12 indicates mild withdrawal, 13 to 24 moderate, 25 to 36 moderately severe, and over 36 severe withdrawal. High-Yield Concept Map: Methadone Considerations in OUD MAT. Mechanism and Agonist Profile. * **What it is**: **Methadone** is a synthetic long-acting **full mu-opioid receptor agonist** that fully binds and activates mu receptors in the central nervous system, suppressing opioid craving and withdrawal while inducing cross-tolerance to illicit opioids. * **First-Line**: Recognized as a gold-standard **first-line** maintenance treatment for moderate to severe **Opioid Use Disorder (OUD)** alongside buprenorphine. * **Why boards care**: Exams test the functional distinction between full agonists (**methadone**), partial agonists (buprenorphine), and antagonists (naltrexone). Regulatory and Clinical Delivery Framework. * **Board Trap**: Prescribers cannot write an outpatient prescription for **methadone** to treat **Opioid Use Disorder (OUD)** in a standard clinic setting. Under SAMHSA regulations, OUD treatment must occur through a certified Opioid Treatment Program (OTP) with daily directly observed dosing until take-home criteria are met. * **Clinical Distinction**: **Methadone** prescribed in standard outpatient practice is legally restricted to pain management, never addiction treatment. Cardiac and Respiratory Safety. * **Safety Alert**: **Methadone** carries a major risk for **QTc prolongation** and torsades de pointes. A baseline ECG is required prior to initiation, with re-evaluation when doses exceed 100 mg daily or when co-administered with QTc-prolonging psychotropics or antimicrobials. * **Toxicity Window**: Due to terminal half-life accumulation (24 to 36 hours), steady state takes 3 to 5 days. Increasing doses too rapidly within 1 to 2 days creates a high risk of lethal respiratory depression. Pregnancy and Special Populations. * **First-Line**: **Methadone** is **first-line** maintenance for pregnant women with **Opioid Use Disorder (OUD)**. Maintenance prevents severe maternal-fetal withdrawal spikes that trigger uterine contractions, miscarriage, or stillbirth. * **Postpartum Expectation**: Neonatal Abstinence Syndrome (NAS) is an expected, treatable outcome in infants exposed to **methadone** in utero and is managed in a specialized neonatal setting. Cytochrome P450 Drug Interactions. * **Inducers**: Co-administration with CYP3A4 inducers (such as carbamazepine, oxcarbazepine, phenytoin, or rifampin) accelerates **methadone** clearance, throwing the patient into acute opioid withdrawal. * **Inhibitors**: Co-administration with CYP3A4 inhibitors (such as fluoxetine, fluvoxamine, or azole antifungals) decreases clearance, causing elevated **methadone** plasma concentrations, excessive sedation, and elevated arrhythmia risk. Spoken Teaching: Opioid Assessment and MAT Protocols. The Clinical Opioid Withdrawal Scale (**COWS**) measures multi-system autonomic and subjective withdrawal signs across 11 key parameters, including resting heart rate, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety, and gooseflesh skin. When scoring the **COWS** scale, a score from 5 to 12 reflects mild withdrawal, 13 to 24 indicates moderate withdrawal, 25 to 36 represents moderately severe withdrawal, and any score over 36 signifies severe withdrawal. For symptomatic withdrawal management without full MAT induction, specific non-opioid adjuncts target individual physiological systems: **clonidine** or lofexidine treats autonomic hyperarousal and diaphoresis, **ondansetron** controls nausea, **loperamide** manages diarrhea, nonsteroidal anti-inflammatory drugs treat muscle and joint aches, and **trazodone** addresses withdrawal-induced insomnia. Comparing the three core FDA-approved medications for **Opioid Use Disorder (OUD)** highlights distinct clinical rules: * **Methadone** is a **full mu-opioid receptor agonist** administered through certified Opioid Treatment Programs (OTPs) that requires no initial withdrawal window before starting. * Buprenorphine is a partial mu-opioid receptor agonist that requires a patient to be in active, mild-to-moderate opioid withdrawal (typically a **COWS** score of 8 to 12) before initiation to prevent precipitating severe acute withdrawal. * Naltrexone is a full opioid antagonist available in oral or long-acting monthly injectable (**Vivitrol**) form that requires a complete opioid-free window of 7 to 14 days prior to administration to avoid precipitating immediate severe withdrawal. Fitzgerald Chapter 11 Sample Practice Questions. Question 1. Match the substance with its characteristic withdrawal symptoms: Statement 1: Muscle cramps, arthralgia, runny nose, tearing, and diarrhea. Statement 2: Depressed mood, fatigue, vivid unpleasant dreams, and psychomotor agitation. Statement 3: Increased heart rate, elevated blood pressure, diaphoresis, coarse hand tremor, agitation, and hallucinations. Which option correctly pairs Statement 1 (Muscle cramps, arthralgia, and diarrhea) with its underlying substance? A) Amphetamines B) Opioids C) Alcohol D) Cannabis Pause. Answer. B. **Why It Is Correct:** Opioid withdrawal produces a multi-system symptom complex characterized by musculoskeletal pain (arthralgia, muscle cramps), gastrointestinal hypermotility (diarrhea, abdominal cramping), autonomic hyperactivity (rhinorrhea, lacrimation, pupillary dilation), and severe restlessness, accurately captured by the **COWS** assessment scale. **Why the Other Choices Are Wrong:** * **A:** Amphetamine withdrawal presents primarily with central nervous system crash symptoms, including severe depression, fatigue, hypersomnia with vivid dreams, and psychomotor slowing or agitation. * **B:** Correct choice. * **C:** Alcohol withdrawal features autonomic hyperarousal, coarse tremors, diaphoresis, hypertension, tachycardia, and potential delirium tremens or seizures rather than isolated aching joints and lacrimation. * **D:** Cannabis withdrawal causes mild irritability, anxiety, sleep disturbance, and decreased appetite without severe systemic muscle cramps or profuse diarrhea. Question 2. Dana, a 44-year-old registered nurse, is preparing for discharge from a 30-day inpatient treatment facility for alcohol and methamphetamine dependence. She wishes to start a medication to help maintain abstinence from alcohol. She mentions that she has extensive dental surgery scheduled within the next month that will require postoperative pain management. Which medication is contraindicated for Dana based on this clinical information? A) Disulfiram B) Naltrexone C) Acamprosate D) Sertraline Pause. Answer. B. **Why It Is Correct:** Naltrexone is a full mu-opioid receptor antagonist. It is strictly contraindicated in patients who are actively taking opioids or who are scheduled to receive opioid analgesics for anticipated surgical or dental procedures, as naltrexone blocks the analgesic effects of prescribed opioids and can precipitate severe withdrawal if opioids are onboard. **Why the Other Choices Are Wrong:** * **A:** Disulfiram causes an unpleasant physical reaction when ethanol is ingested but does not block opioid receptors, making it safe regarding anticipated perioperative opioid use. * **C:** Acamprosate modulates glutamate and GABA neurotransmission to maintain alcohol abstinence and is cleared renally without affecting opioid receptors or liver enzymes. * **D:** Sertraline is a selective serotonin reuptake inhibitor used for depression or anxiety that does not interfere with mu-opioid receptor binding during planned dental surgery. 💡 **Next Study Step:** Review Buprenorphine induction protocols, precipitation risks, and the **COWS** scale scoring thresholds in Chapter 11 to master partial agonist psychopharmacology for board exam scenarios. Next. New section. Laboratory Findings in AUD (Table 11-5). Topic. AST/ALT Ratio Significance. Bottom Line. - **AST to ALT ratio**: An **AST** greater than **ALT** (AST:ALT ratio greater than 2:1) within 3 times the upper limit of normal strongly indicates heavy alcohol consumption or **alcohol use disorder**. - **Enzyme resolution timeline**: Transaminase elevations (**AST** and **ALT**) return to baseline within 1 to 3 months of sustained sobriety. - **Macrocytosis without anemia**: Elevated **MCV** (greater than 96 fL, such as 105 fL) with normal hemoglobin and hematocrit occurs in 60% of heavy drinkers (3 or more drinks per day in women, 5 or more in men). - **MCV resolution timeline**: Macrocytosis normalizes within 2 to 3 months of sustained sobriety. - **Isolated hypertriglyceridemia**: Elevated triglycerides (such as 325 mg/dL) with relatively normal HDL and LDL resolves within 1 to 2 months of sobriety. - **First-line AUD pharmacotherapy in liver disease**: **Acamprosate** is cleared by the kidneys and is safe in liver impairment, whereas **naltrexone** is contraindicated in acute hepatitis or liver failure. High-Yield Concept Map: AST/ALT Ratio and AUD Laboratory Findings. AST to ALT Ratio Significance. - **What it is**: In heavy alcohol consumption, serum **AST** is elevated higher than **ALT**, typically remaining within 2 to 3 times the upper limit of normal (for example, AST 83 U/L vs ALT 50 U/L, where normal is 0 to 40 U/L) [1, 2]. - **Why boards care**: Exams test your ability to differentiate alcohol-induced hepatic stress from primary viral hepatitis based on enzyme patterns and ratios [2, 3]. - **Must know criteria**: An **AST** value higher than **ALT** with levels up to 3 times the upper limit of normal points to alcohol [1, 2]. Conversely, **ALT** higher than **AST** points toward viral hepatitis [2, 3]. - **Typical board clue**: A middle-aged or young adult with an AST of 83 U/L and ALT of 50 U/L who presents with social or academic decline [1, 2]. - **First-line**: Assess drinking patterns using the **CAGE** or **AUDIT** questionnaire, order baseline liver function tests, and counsel on sobriety [4-6]. - **When the answer changes**: If the patient has co-existing liver failure or acute hepatitis, **naltrexone** becomes contraindicated, making **acamprosate** the first-line pharmacotherapy [7-9]. - **Safety alert**: Never start **naltrexone** in patients with active liver failure, acute hepatitis, or ongoing opioid use [7, 10, 11]. - **Board trap**: Mistaking mild transaminase elevation (AST 83 U/L, ALT 50 U/L) for acute viral hepatitis and ordering invasive workups instead of taking a thorough substance history [1, 3]. Macrocytosis and Lipid Markers in AUD. - **What it is**: Mild macrocytosis (**MCV** greater than 96 fL, such as 105 fL) without anemia (normal hemoglobin 15 g/dL and hematocrit 45%), along with isolated hypertriglyceridemia (triglycerides 325 mg/dL) [12-14]. - **Why boards care**: These objective laboratory findings serve as covert biological markers for chronic heavy alcohol use when a patient minimizes intake or is in denial [6, 12]. - **Must know timelines**: Transaminases resolve in 1 to 3 months of sobriety, macrocytosis resolves in 2 to 3 months of sobriety, and hypertriglyceridemia resolves in 1 to 2 months of sobriety [2, 12, 15]. - **Fast memory hook**: Remember the lab recovery order: Triglycerides normalize fastest (1 to 2 months), transaminases next (1 to 3 months), and red blood cell size last (2 to 3 months due to RBC lifespan) [2, 12, 15]. Compare and Distinguish: AUD Lab Findings vs. Viral Hepatitis. Alcohol-Induced Liver Strain vs. Viral Hepatitis. - **Do not confuse**: Alcohol-related enzyme changes show **AST** greater than **ALT**, whereas viral hepatitis shows **ALT** greater than **AST** [2, 3]. - **Think Alcohol when**: AST is higher than ALT and both are mildly elevated (under 3 times normal limits), accompanied by elevated MCV or triglycerides [1, 2, 12, 15]. - **Think Viral Hepatitis when**: ALT is significantly higher than AST, often reaching hundreds or thousands of units per liter [2, 3]. - **Priority difference**: Alcohol-induced elevations require substance assessment and lifestyle intervention; acute viral hepatitis requires infectious disease workup and hepatic monitoring [3, 6]. - **What boards are testing**: Recognizing that the "L" in ALT stands for primary Liver/hepatitis injury, while AST predominates in alcohol toxicity [2, 3]. - **Classic distractor**: Ordering viral hepatitis serologies for a mild AST 83 U/L / ALT 50 U/L elevation without first asking about daily beer consumption [1, 3]. Practice Questions: Chapter 11 Review. Question 1. Q1. A 58-year-old man with a 10-year history of alcohol abuse presents for routine laboratory evaluation source 1. His serum AST is 83 U/L (normal 0 to 40 U/L) and ALT is 50 U/L (normal 0 to 40 U/L) source 2. Which of the following statements regarding these laboratory findings is correct? A. ALT elevation exceeding AST is characteristic of chronic alcohol use. B. Transaminase elevations from heavy alcohol use typically exceed 10 times the upper limit of normal. C. The elevated AST to ALT ratio usually resolves within 1 to 3 months of sustained sobriety. D. These lab values indicate acute viral hepatitis requiring immediate liver biopsy. Pause. Answer: C source 2. Why it is correct: In alcohol use disorder, AST is characteristically higher than ALT, typically remaining within 3 times the upper limit of normal source 1. These enzyme elevations resolve within 1 to 3 months of sustained sobriety source 2. Why the other choices are wrong: - A: Incorrect because AST exceeding ALT is characteristic of alcohol use, whereas ALT exceeding AST indicates primary hepatitis [2, 3]. - B: Incorrect because alcohol-induced transaminase elevations are typically modest, remaining within 3 times the upper limit of normal rather than 10 times [1, 2]. - D: Incorrect because an AST of 83 U/L and ALT of 50 U/L reflect mild alcohol-induced hepatic strain, not acute viral hepatitis or an indication for liver biopsy [1, 3]. Question 2. Q2. Gary, a 54-year-old man with a history of alcohol use disorder and moderate chronic liver disease, has been abstinent for 3.5 years [16, 17]. At a follow-up visit, he reports severe life stress following the death of his sibling and job loss, stating he feels strong urges to drink source 17. Which medication is recommended to help prevent relapse in this patient? A. Disulfiram B. Naltrexone C. Acamprosate D. Lorazepam Pause. Answer: C source 18. Why it is correct: **Acamprosate** is cleared by the kidneys and is safe to use in patients with underlying liver disease [8, 9]. It helps maintain abstinence by restoring GABA and glutamate balance source 8. Why the other choices are wrong: - A: Incorrect because disulfiram is an aversion agent used with caution in liver disease and is not preferred initial therapy source 19. - B: Incorrect because **naltrexone** is contraindicated in acute hepatitis or significant liver failure due to risks of hepatotoxicity [7, 9]. - D: Incorrect because benzodiazepines like lorazepam are used for acute withdrawal management, not for long-term relapse prevention in an outpatient [9, 20]. Question 3. Q3. Dana, a 44-year-old woman with alcohol use disorder, is scheduled to undergo extensive dental work requiring postoperative opioid analgesics in two weeks [10, 11, 21]. She requests medication to help maintain alcohol abstinence source 21. Which agent is contraindicated for this patient? A. Disulfiram B. Naltrexone C. Acamprosate D. Sertraline Pause. Answer: B source 10. Why it is correct: **Naltrexone** blocks mu-opioid receptors source 7. If given to a patient who requires opioid pain management for dental procedures, it will block the analgesic effects or precipitate severe withdrawal if opioids are used [7, 11]. Why the other choices are wrong: - A: Incorrect because disulfiram does not interact with opioid receptors, though it requires strict avoidance of alcohol [11, 19]. - C: Incorrect because **acamprosate** acts on GABA and glutamate pathways and does not interfere with opioid pain management [8, 11]. - D: Incorrect because sertraline is an SSRI used for depression or anxiety, not an AUD relapse prevention agent, and is not specifically contraindicated for upcoming opioid use [11, 22]. Question 4. Q4. A 48-year-old man with a long history of heavy drinking presents for a wellness exam. Lab results show a normal hemoglobin of 15 g/dL and hematocrit of 45%, but an MCV of 105 fL (normal 80 to 96 fL) source 13. He asks how long it will take for his red blood cell size to return to normal if he stops drinking. What is the correct response? A. 1 to 2 weeks B. 1 to 2 months C. 2 to 3 months D. 6 to 12 months Pause. Answer: C source 12. Why it is correct: Mild macrocytosis without anemia develops in approximately 60% of heavy drinkers and resolves within 2 to 3 months of sustained sobriety as new red blood cells are produced source 12. Why the other choices are wrong: - A: Incorrect because red blood cell turnover takes time, so MCV cannot normalize within 1 to 2 weeks. - B: Incorrect because 1 to 2 months is the timeline for triglyceride normalization, whereas MCV normalization requires 2 to 3 months [12, 15]. - D: Incorrect because 6 to 12 months is unnecessarily long; erythrocyte parameters normalize within 2 to 3 months of abstinence source 12. Active Recall Checkpoints. 1. What is the characteristic AST to ALT relationship seen in alcohol use disorder, and what is its typical upper boundary [1, 3]? 2. How many months of sustained sobriety are required for AST and ALT levels to normalize source 2? 3. What percentage of heavy drinkers exhibit macrocytosis without anemia, and what is the resolution timeline source 12? 4. Which AUD relapse prevention medication is preferred in a patient with liver impairment [8, 9]? 5. Which AUD relapse prevention medication is contraindicated in a patient who requires upcoming surgical opioid analgesia [7, 11]? Next Study Step. The single best next topic to study is **Pharmacotherapy for Alcohol Dependence and Withdrawal Protocols (CIWA-Ar vs CAGE/AUDIT)**. Studying this next solidifies the transition from laboratory detection to acute stabilization and long-term maintenance planning. 💡 Want to test your knowledge further? I can generate a 10-question board-style practice quiz focusing on substance withdrawal protocols and pharmacotherapy selection. Next. End of this drive.